FABLE THERAPEUTICS

What this means for you

Approved and waiting on proof of use. It will register unless the applicant drops it, and its 12 Nov 2024 filing date already counts against anyone who files later.

Record

Serial number

98849309

Mark type

Stylized text

Filed

12 Nov 2024

Published for opposition

07 Oct 2025

Attorney of record

Aaron D. Hendelman

Goods and services

• Class 042 — Scientific and technological services: Research and development of biological and pharmaceutical drugs to treat diseases utilizing a proprietary drug discovery platform; drug discovery services; pharmaceutical research and development services; providing online non-downloadable computer software for collecting, analyzing, reporting, and tracking data and information in the fields of biotechnology and pharmaceuticals; software as a service (SAAS) services featuring software for collecting, analyzing, reporting, and tracking data and information in the fields of biotechnology and pharmaceuticals; providing online non-downloadable computer software for use in generating, analyzing, and accessing data via artificial intelligence and machine learning; software as a service (SAAS) services featuring software for use in generating, analyzing, and accessing data via artificial intelligence and machine learning; providing an online non-downloadable computer software platform for discovering proteins and drugs, forecasting potential uses of proteins and drug compounds and generating insights from screening and analyzing molecules, featuring software using artificial intelligence and machine learning; providing temporary use of non-downloadable computer software for discovering proteins and drugs, forecasting potential uses of proteins and drug compounds and generating insights from screening and analyzing molecules, all using artificial intelligence and machine learning; software as a service (SAAS) services featuring software for discovering proteins and drugs, forecasting potential uses of proteins and drug compounds and generating insights from screening and analyzing molecules, all using artificial intelligence and machine learning; providing an online non-downloadable computer software platform for analyzing molecular data; providing temporary use of non-downloadable computer software for generating and analyzing molecular data for biotechnology and pharmaceutical companies; software as a service (SAAS) services featuring software for generating and analyzing molecular data for biotechnology and pharmaceutical companies; preclinical drug discovery and development services used for identifying, designing, and optimizing chemical and biological compounds; pharmaceutical evaluation and preclinical evaluation of biological and chemical series and biological and chemical compounds in drug discovery; pharmaceutical drug development and discovery services, namely, identifying, designing, optimizing, and developing biological and chemical series and biological and chemical compounds via software using artificial intelligence and machine learning; providing an online searchable database in the fields of proteins and pharmaceuticals for scientific research purposes, in particular, pharmaceutical research and development, scientific research and development of proteins and pharmaceutical preparations, scientific development of new uses for proteins and pharmaceutical compounds, and scientific technical research; scientific research and development for forecasting the use of molecules as diagnostics, prognostics, and drug compounds and developing new uses for pharmaceutical compounds; research and development in the field of drug discovery and development, diagnostics and prognostics; drug discovery services, namely, discovering novel molecules to develop into drug compounds; medical research and development in the field of biopharmaceuticals, diagnostics, prognostics, and protein engineering

Owner

• Fable Therapeutics, Inc., Cambridge, MA, US
• Fable Therapeutics, Inc., Cambridge, MA, US

Prosecution history

• 02 Dec 2025 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
• 07 Oct 2025 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
• 07 Oct 2025 — PUBLISHED FOR OPPOSITION
• 01 Oct 2025 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
• 04 Sept 2025 — APPROVED FOR PUB - PRINCIPAL REGISTER
• 11 Aug 2025 — TEAS/EMAIL CORRESPONDENCE ENTERED
• 11 Aug 2025 — CORRESPONDENCE RECEIVED IN LAW OFFICE
• 11 Aug 2025 — TEAS RESPONSE TO OFFICE ACTION RECEIVED
• 13 May 2025 — NOTIFICATION OF NON-FINAL ACTION E-MAILED
• 13 May 2025 — NON-FINAL ACTION E-MAILED
• 13 May 2025 — NON-FINAL ACTION WRITTEN
• 08 May 2025 — ASSIGNED TO EXAMINER
• 26 Apr 2025 — NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
• 12 Nov 2024 — NEW APPLICATION ENTERED